Novolin
NDC 64725-1834

View NDC Profile UNII Mappings and RxNorm Concepts.

Product Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Novolin is a NDA-approved product labeled by Tya Pharmaceuticals. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 64725-1834 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.

Primary Identification

NDC Product Code:
64725-1834
Proprietary Name:
Novolin N
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Code Navigator:

Labeler & Regulatory Data

Labeler Code:
64725
FDA Application Number: [6]
NDA019959
Marketing Category: [8]
NDA - A product marketed under an approved New Drug Application.

Marketing Timeline

Start Marketing Date: [9]
07-01-1991
Listing Expiration Date: [11]
12-31-2017
Exclude Flag: [12]
I

Code Structure Chart

Product Details

What is NDC 64725-1834?

The NDC code 64725-1834 is assigned by the FDA to the product Novolin N. This pharmaceutical product is labeled by Tya Pharmaceuticals and is currently categorized as listed product. In terms of distribution, this product is available in a single package configuration. The associated package NDC(s) include: 64725-1834-1. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.

What are the uses of this product?

Talk to your healthcare provider if you have any questions. Your healthcare provider should show you how to inject Novolin N before you start taking it. Follow your healthcare provider’s instructions to make changes to your insulin dose. Read the instructions for use that come with your Novolin N product. ®®•Take Novolin N exactly as prescribed. ®The effects of Novolin N start working 1½ hours after injection. •Novolin N is an intermediate-acting insulin. ®®The greatest blood sugar lowering effect is between 4 and 12 hours after the injection. This blood sugar lowering may last up to 24 hours. •any change of insulin should be made cautiously and only under medical supervision. Doses of oral anti-diabetic medicines may also need to change, if your insulin is changed. •While using Novolin N, ®with any insulins other than Regular human insulin in the same syringe. •Do not mix Novolin N ®Novolin N may affect your blood sugar levels sooner if you inject it into the skin of your stomach area. •Inject Novolin N into the skin of your stomach area, upper arms, buttocks or upper legs. ®®Never inject Novolin N into a vein or into a muscle. ®•Change (rotate) your injection site within the chosen area (for example, stomach or upper arm) with each dose. Do not inject into the same spot for each injection.You can treat mild low blood sugar (hypoglycemia) by drinking or eating something sugary right away (fruit juice, sugar candies, or glucose tablets). It is important to treat low blood sugar (hypoglycemia) right away because it could get worse and you could pass out (become unconscious). If you pass out, you will need help from another person or emergency medical services right away, and will need treatment with a glucagon injection or treatment at a hospital. See “What are the possible side effects of Novolin N?” for more information on low blood sugar (hypoglycemia). •If you take too much Novolin  N, your blood sugar may fall low (hypoglycemia). ®® If  high blood sugar (hyperglycemia) is not treated it can lead to diabetic ketoacidosis, which can lead to serious problems, like loss of consciousness (passing out), coma or even death. Follow your healthcare provider’s instructions for treating high blood sugar (hyperglycemia), and talk to your healthcare provider if high blood sugar is a problem for you. Severe or continuing high blood sugar (hyperglycemia) requires prompt evaluation and treatment by your healthcare provider. Know your symptoms of high blood sugar (hyperglycemia) and diabetic ketoacidosis which may include: •If you forget to take your dose of Novolin  N, your blood sugar may go too high (hyperglycemia). ®increased thirst •fruity smell on breath •frequent urination and dehydration •high amounts of sugar and ketones in your urine •confusion or drowsiness •nausea, vomiting (throwing up) or stomach pain •loss of appetite •a hard time breathing •Ask your healthcare provider how often you should check your blood sugar levels for hypoglycemia (too low blood sugar) and hyperglycemia (too high blood sugar). Check your blood sugar levels.Your insulin dosage may need to change because of:illness •change in diet •stress •change in physical activity or exercise •other medicines you take •surgery •See the end of this patient information for instructions about preparing and giving the injection. What should I avoid while using Novolin N? ®Alcohol, including beer and wine, may affect your blood sugar when you take Novolin N. •Alcohol.®You may have difficulty concentrating or reacting if you have low blood sugar (hypoglycemia). Be careful when you drive a car or operate machinery. Ask your healthcare provider if it is alright to drive if you often have: •Driving and operating machinery.low blood sugar ∘decreased or no warning signs of low blood sugar ∘What are the possible side effects of Novolin N? ®Symptoms of hypoglycemia (low blood sugar) may include: •Low blood sugar (hypoglycemia).sweating •trouble concentrating or confusion •dizziness or lightheadedness •blurred vision •shakiness •slurred speech •hunger •anxiety, irritability or mood changes •fast heart beat •headache •tingling of lips and tongue •Severe low blood sugar (hypoglycemia) can cause unconsciousness (passing out), seizures, and death. Know your symptoms of low blood sugar. Follow your healthcare provider’s instructions for treating low blood sugar. Talk to your healthcare provider if low blood sugar is a problem for you.a rash over your whole body, have trouble breathing, a fast heartbeat, or sweating. •Serious allergic reaction (whole body reaction). Get medical help right away if you developYou may get redness, swelling, and itching at the injection site. If you keep having skin reactions, or they are serious, talk to your healthcare provider. You may need to stop using Novolin N and use a different insulin. Do not inject insulin into skin that is red, swollen, or itchy. •Reactions at the injection site (local allergic reaction).®Change (rotate) where you inject your insulin to help prevent these skin changes from happening. Do not inject insulin into this type of skin. •Skin thickens or pits at the injection site (lipodystrophy).•Swelling of your hands and feetTaking certain diabetes pills called thiazolidinediones or “TZDs” with Novolin N may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with Novolin N. Your healthcare provider should monitor you closely while you are taking TZDs with Novolin N. Tell your healthcare provider if you have any new or worse symptoms of heart failure including: •Heart Failure.®®®shortness of breath ∘swelling of your ankles or feet ∘sudden weight gain ∘Treatment with TZDs and Novolin N may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure.  ®•Vision changes•Low potassium in your blood (hypokalemia)These are not all of the possible side effects from Novolin N. Ask your healthcare provider or pharmacist for more information. ®Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should I store Novolin N? ®All Unopened Novolin N: ®° ° ° ° •Keep all unopened Novolin N in the refrigerator between 36 ®to 46F (2to 8C).Do not freeze. Do not use Novolin N if it has been frozen. •®If refrigeration is not possible, the unopened vial may be kept at room temperature for up to 6 weeks (42 days), as long as it is kept at or below 77°F (25°C). •Keep unopened Novolin N in the carton to protect from light. •®Novolin N in use: ®VialsKeep at room temperature below 77°F (25°C) for up to 6 weeks (42 days). •Keep vials away from direct heat or light. •Throw away an opened vial after 6 weeks (42 days) of use, even if there is insulin left in the vial. •Unopened vials can be used until the expiration date on the Novolin N label, if the medicine has been stored in a refrigerator. •®General advice about Novolin N ®Novolin N is used for the treatment of diabetes only. Medicines are sometimes prescribed for conditions that are not mentioned in the patient leaflet. Do not use Novolin N for a condition for which it was not prescribed. Do not give Novolin N to other people, even if they have the same symptoms you have. It may harm them. ®®®This leaflet summarizes the most important information about Novolin N. If you would like more information about Novolin N or diabetes, talk with your healthcare provider. For more information, call 1-800-727-6500 or visit www.novonordisk-us.com. ®®Helpful information for people with diabetes is published by the American Diabetes Association, 1701 N Beauregard Street, Alexandria, VA 22311 and on www.diabetes.org.

Which are the associated UNII Codes?

The UNII codes for the active ingredients in this product are:

Which are the Inactive Ingredients associated UNII Codes?

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

What is the NDC to RxNorm Crosswalk for this product?

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
  • RxCUI: 311027 - NovoLIN N 100 UNT/ML Injectable Suspension
  • RxCUI: 311027 - insulin isophane, human 100 UNT/ML Injectable Suspension [Novolin N]
  • RxCUI: 311027 - Novolin N 100 UNT/ML Injectable Suspension
  • RxCUI: 311027 - ReliOn Novolin N 100 UNT/ML Injectable Suspension
  • RxCUI: 311028 - insulin isophane (NPH), human 100 UNT/mL Injectable Suspension

* Please review the full disclaimer at the bottom of this page.

Product & Regulatory Definitions
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".